Coya Therapeutics, Inc.
COYA
$6.15
$0.172.84%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -95.22% | 103.39% | -99.97% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -95.22% | 103.39% | -99.97% | -- |
| Cost of Revenue | 31.16% | -19.78% | 66.15% | 20.37% | 39.67% |
| Gross Profit | 129.11% | -206.73% | -64.59% | -144.06% | -39.67% |
| SG&A Expenses | 15.22% | 39.25% | 11.23% | -10.07% | 12.95% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.16% | -1.25% | 42.08% | 2.21% | 24.86% |
| Operating Income | 56.93% | -98.22% | -40.65% | -303.17% | -24.86% |
| Income Before Tax | 47.39% | -110.78% | -44.63% | -282.74% | -17.52% |
| Income Tax Expenses | -- | -- | -- | -199.50% | -- |
| Earnings from Continuing Operations | 47.39% | -110.78% | -44.63% | -330.32% | -17.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 47.39% | -110.78% | -44.63% | -330.32% | -17.52% |
| EBIT | 56.93% | -98.22% | -40.65% | -303.17% | -24.86% |
| EBITDA | 57.01% | -98.42% | -40.70% | -302.14% | -24.91% |
| EPS Basic | 52.16% | -87.93% | -25.07% | -255.45% | 23.20% |
| Normalized Basic EPS | 63.78% | -87.95% | -25.68% | -212.38% | 23.21% |
| EPS Diluted | 52.16% | -87.93% | -25.07% | -255.45% | 23.20% |
| Normalized Diluted EPS | 63.78% | -87.95% | -25.68% | -212.38% | 23.21% |
| Average Basic Shares Outstanding | 9.93% | 12.13% | 15.65% | 48.23% | 53.01% |
| Average Diluted Shares Outstanding | 9.93% | 12.13% | 15.65% | 48.23% | 53.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |